Advanced Filters
noise
Found 2,256 clinical trials
A Adrienne G Waks, MD

VS-6766+Abema+Fulv in Met HR+/HER- BC

This research is being done to evaluate the safety and effectiveness of a drug currently known as VS-6766 in combination with the drugs abemaciclib and fulvestrant in HR+/HER2-negative breast cancer. The names of the study drugs involved in this study are: VS-6766 Abemaciclib Fulvestrant

18 years of age All Phase 1/2
C Carly Sronce, BSN, RN-BC

Comparison of CE-DBT and MRI in Patients With Known Breast Lesions

The purpose of this pilot study is to compare radiologist confidence level in evaluating patients with known breast lesions between contrast enhanced digital breast tomosynthesis (CE- DBT) and contrast enhanced dynamic magnetic resonance imaging (CE-MRI) acquired as a part of a standard clinical workup.

18 years of age Female Phase N/A

Study of 18F-FFNP Breast PET/MRI

This clinical trial will investigate an estrogen-regulated parameter as an early measure of endocrine therapy response: progesterone receptor (PR) protein with a progestin-based radioligand, 18F-fluorofuranylnorprogesterone (18F-FFNP). The overall purpose of this research is to test the efficacy of 18F-FFNP PET/MRI for predicting response to presurgical endocrine therapy and to determine …

18 years of age Female Phase 2

Single Pre-Operative Radiation Therapy - With Delayed or No Surgery (SPORT-DNS)

Eligible women will receive neoadjuvant single fraction radiotherapy followed by surgery performed after one year

50 years of age Female Phase N/A
R R. Iqbal, MD

Dynamic and Test-retest Whole Body [18F]FES PET Imaging in Patients With Metastatic ER+ Breast Cancer

16a-18F-fluoro-17b-estradiol ([18F]FES) is radioactive labeled estradiol, developed for in vivo visualization of the estrogen receptor (ER) using positron emission tomography (PET). To date, [18F]FES PET has been mainly explored as a diagnostic imaging tool to assess ER expression, thereby identifying locations of disease and their potential sensitivity to endocrine therapy, …

18 years of age Female Phase N/A
S Sarah Lansdowne

KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer

This is a study aimed at testing a commonly available and inexpensive chemical (hydrogen peroxide) for efficacy in sensitising large cancerous lumps in the breast to a standard course of radiotherapy in patients with locally advanced or recurrent breast cancer. Laboratory research and initial clinical trials in Japan suggest that …

18 years of age All Phase 2
G Gosala Gopalakrishnan, PhD

HERPET- A Novel PET Imaging Study of HER2 in Breast Cancer

This mechanistic study will be the first study to assess the efficacy of [18F]GE-226 to target HER2 expression in patients with metastatic breast cancer. The study will establish the pharmacokinetics of [18F]GE-226 and the optimum time-point for performing static scans in this patient population.

18 years of age Female Phase N/A
M M Kok, MD

Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO

To determine whether short-term pre-operative nivolumab either as monotherapy or in combination with low dose doxorubicin or novel IO combinations can induce immune activation in early BC.

18 years of age Female Phase 2
M Maria E Lendorf

Effects of Cryotherapy on Taxane-Induced Neuropathy in Patients With Breast Cancer

Due to well-proven survival benefit, paclitaxel and other taxane-based chemotherapies are first-line agents for both the adjuvant and neoadjuvant treatment of early stage breast cancer. Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent and disabling side effect of taxane anticancer agents. No established strategy exists for CIPN prevention. This study is …

18 years of age All Phase N/A

Prospective Surveillance for Breast Cancer-Related Lymphedema

This randomized trial will test the effect of a prospective surveillance program for early detection and subclinical management of breast cancer-related lymphedema on the prevalence of chronic lymphedema.

18 years of age All Phase N/A

Simplify language using AI